Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC
Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
In recent years, with the progress in the treatment field, Non-Small Cell Lung Cancer(NSCLC)
has become the most successful cancer species in precision medicine. Patients with positive
driving genes such as EGFR, ALK, ROS1, BRAF and so on have clearly targeted drugs, which
bring survival benefits to patients.However, about 50% of patients still lack a clear driving
gene target, which has become the focus of current research.In the field of wild-type NSCLC
with negative driver genes, the classic first-line treatment regimen is the two-drug regimen
containing platinum.The study by Kimura T in the first-line treatment of 54 wild-type
advanced NSCLC patients with carboplatin and pemetrexed showed that the ORR, mPFS and mOS of
patients with wild-type non-squamous NSCLC treated with carboplatin permetrexine were 35.8%,
5.4 months and 12.7 months respectively.
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and
development.In the phase Ⅲ study, patients who failed at least two kinds of systemic
chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib or
placebo, the anlotinib group PFS and OS were 5.37 months and 9.46 months, the placebo group
PFS and OS were 1.4 months and 6.37 months.
The efficacy and safety of Anlotinib combined with Pemetrexed and Carboplatin followed by
maintenance therapy with Anlotinib plus Pemetrexed as the first-line treatment in patients
with advanced nonsquamous NSCLC deserve further exploration.